Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / EGRX - Eagle Pharmaceuticals Non-GAAP EPS of $0.85 misses by $0.09 revenue of $42.32M misses by $8.76M

EGRX - Eagle Pharmaceuticals Non-GAAP EPS of $0.85 misses by $0.09 revenue of $42.32M misses by $8.76M

Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q4 Non-GAAP EPS of $0.85 misses by $0.09. Revenue of $42.32M (-15.2% Y/Y) misses by $8.76M. “With two important launches in early 2022, Eagle is off to a great start. The initial impressive revenue generated from vasopressin and PEMFEXY, each with significant periods of exclusivity, together with our royalties from bendamustine sales in Japan, position us to more than double our earnings this year. Based on early 2022 trends, we believe that our Q1 2022 earnings per share should approximate $4.00. Our pipeline is advancing as expected, and our balance sheet remains healthy. The period ahead will be exciting for us as we plan to deploy our cash to strengthen our product offerings and grow the company,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

For further details see:

Eagle Pharmaceuticals Non-GAAP EPS of $0.85 misses by $0.09, revenue of $42.32M misses by $8.76M
Stock Information
Company Name: Eagle Pharmaceuticals Inc.
Stock Symbol: EGRX
Market: NASDAQ
Website: eagleus.com
Menu
EGRX EGRX Quote EGRX Short EGRX News EGRX Articles EGRX Message Board
Get EGRX Alerts

News, Short Squeeze, Breakout and More Instantly...